Allergic immune response

The allergic immune response is a complex physiological process characterized by an exaggerated immune reaction to typically harmless environmental substances known as allergens. This response is fundamentally a Type I hypersensitivity reaction, which begins with a sensitization phase where B cells produce allergen-specific Immunoglobulin E (IgE) antibodies (StatPearls, 2023). These IgE antibodies bind to the high-affinity FcεRI receptors on the surface of mast cells and basophils; upon subsequent allergen exposure, cross-linking of these receptors triggers the rapid degranulation and release of preformed mediators like histamine, as well as the synthesis of leukotrienes and prostaglandins (NIH, 2022). This immediate phase causes classic symptoms such as sneezing, itching, and vasodilation, while a subsequent late-phase response involves the recruitment of eosinophils and T-helper 2 (Th2) cells, driven by cytokines like IL-4, IL-5, and IL-13 (Nature Reviews Immunology, 2018). Pharmacological management targets various nodes within this cascade, including the use of monoclonal antibodies to sequester IgE (e.g., omalizumab) or block cytokine receptors (e.g., dupilumab), alongside small molecules that antagonize the downstream effects of released mediators (PubMed, 2021). Because this term describes a broad biological pathway rather than a single molecular entity like a receptor or enzyme, it is classified as a physiological process rather than a specific therapeutic target.

Other names

Type I hypersensitivityAtopyAllergic reactionIgE-mediated hypersensitivityImmediate hypersensitivity

Therapeutic strategies involve neutralizing circulating IgE antibodies, blocking Th2-associated cytokine signaling (IL-4, IL-5, IL-13), antagonizing histamine (H1) or leukotriene receptors, and stabilizing mast cells to prevent the release of inflammatory mediators.